Literature DB >> 25780292

Tumor suppressor role of miR-133a in gastric cancer by repressing IGF1R.

Yu Gong1, Jun Ren1, Kun Liu1, Li-Ming Tang1.   

Abstract

AIM: To investigate the function and mechanism of miR-133a in gastric cancer (GC) and its relationship with clinicopathological characteristics of GC.
METHODS: A total of 105 GC patients who underwent surgical resection as primary treatment were selected for this study. Real-time quantitative reverse transcriptase polymerase chain (qRT-PCR) was used to examine the expression levels of miR-133a in human GC and adjacent non-tumor tissues, as well as in GC cell lines (SGC-7901, BGC-823, MGC-803, and AGS) and a human gastric mucosal epithelial cell line (GES-1). The biological role of miRNA (miR)-133a was assessed in the GC cell lines using MTT, apoptosis, migration and invasion, and colony formation assays, and xenograft tumorigenesis. qRT-PCR and western blot analyses were used to evaluate the potential target gene expression of miR-133a. Pearson's correlation was calculated to evaluate the correlation between miR-133a and insulin-like growth factor 1 receptor (IGF1R) expression. The regulation of IGF1R by miR-133a was verified using the luciferase reporter assay.
RESULTS: In 80% of the 105 GC patients, the mean expression of miR-133a was significantly downregulated in tumor tissues compared with adjacent normal tissues (1.215 ± 0.1477 vs 3.093 ± 0.4104, P < 0.0001). Downregulation of miR-133a was significantly correlated with the degree of differentiation (P = 0.01), local invasion (P = 0.001) and TNM stage (P = 0.02) in GC patients. Compared with a control construct, forced expression of miR-133a in GC cell lines inhibited proliferation (0.4787 ± 0.0219 vs 0.7050 ± 0.0147, P = 0.0013 in SGC-7901 cells; and 0.5448 ± 0.0085 vs 0.7270 ± 0.0084, P = 0.001 in MGC-803 cells); migration (0.6333 ± 0.0233 vs 1.037 ± 0.0584, P = 0.003 in SGC-7901 cells; 0.6126 ± 0.0311 vs 1.024 ± 0.0456, P = 0.0017 in MGC-803 cells); and invasion (0.613 ± 0.0399 vs 1.033 ± 0.0278, P = 0.0013 in SGC-7901 cells; 0.7433 ± 0.0221 vs 1.017 ± 0.0311, P = 0.002 in MGC-803 cells). It also induced apoptosis (18.19% ± 0.2483% vs 5.887% ± 0.3837%, P < 0.0001 in SGC-7901 cells; 22.69% ± 0.7846% vs 9.347% ± 0.3012%, P < 0.0001 in MGC-803 cells). Furthermore, miR-133a inhibited tumor growth and xenograft tumorigenesis of SGC -7901 cells in vivo. In addition, we identified IGF1R as a regulatory target of miR-133a in GC.
CONCLUSION: This study suggests that miR-133a is downregulated in GC and functions as a tumor suppressor in vitro and in vivo partly by repressing IGF1R.

Entities:  

Keywords:  Gastric cancer; Insulin-like growth factor 1 receptor; Tumor suppressor; miR-133a

Mesh:

Substances:

Year:  2015        PMID: 25780292      PMCID: PMC4356914          DOI: 10.3748/wjg.v21.i10.2949

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  27 in total

1.  Causes of cancer in the world: comparative risk assessment of nine behavioural and environmental risk factors.

Authors:  Goodarz Danaei; Stephen Vander Hoorn; Alan D Lopez; Christopher J L Murray; Majid Ezzati
Journal:  Lancet       Date:  2005-11-19       Impact factor: 79.321

2.  MiR-145, miR-133a and miR-133b inhibit proliferation, migration, invasion and cell cycle progression via targeting transcription factor Sp1 in gastric cancer.

Authors:  Tianzhu Qiu; Xin Zhou; Jian Wang; Yiping Du; Jun Xu; Zebo Huang; Wei Zhu; Yongqian Shu; Ping Liu
Journal:  FEBS Lett       Date:  2014-03-05       Impact factor: 4.124

3.  Differential expression of microRNA species in human gastric cancer versus non-tumorous tissues.

Authors:  Junming Guo; Ying Miao; Bingxiu Xiao; Rong Huan; Zhen Jiang; Dan Meng; Yanjun Wang
Journal:  J Gastroenterol Hepatol       Date:  2008-11-03       Impact factor: 4.029

4.  Tumor suppressor functions of miR-133a in colorectal cancer.

Authors:  Yujuan Dong; Junhong Zhao; Chung-Wah Wu; Lijing Zhang; Xiaodong Liu; Wei Kang; Wing-Wah Leung; Ning Zhang; Francis K L Chan; Joseph J Y Sung; Simon S M Ng; Jun Yu
Journal:  Mol Cancer Res       Date:  2013-05-30       Impact factor: 5.852

5.  MicroRNA-143 inhibits tumor growth and angiogenesis and sensitizes chemosensitivity to oxaliplatin in colorectal cancers.

Authors:  Xu Qian; Jing Yu; Yu Yin; Jun He; Lin Wang; Qi Li; Lou-Qian Zhang; Chong-Yong Li; Zhu-Mei Shi; Qing Xu; Wei Li; Li-Hui Lai; Ling-Zhi Liu; Bing-Hua Jiang
Journal:  Cell Cycle       Date:  2013-04-08       Impact factor: 4.534

6.  microRNA-133a regulates the cell cycle and proliferation of breast cancer cells by targeting epidermal growth factor receptor through the EGFR/Akt signaling pathway.

Authors:  Wenjing Cui; Shuai Zhang; Changliang Shan; Li Zhou; Zhemin Zhou
Journal:  FEBS J       Date:  2013-07-10       Impact factor: 5.542

7.  The tumour-suppressive function of miR-1 and miR-133a targeting TAGLN2 in bladder cancer.

Authors:  H Yoshino; T Chiyomaru; H Enokida; K Kawakami; S Tatarano; K Nishiyama; N Nohata; N Seki; M Nakagawa
Journal:  Br J Cancer       Date:  2011-02-08       Impact factor: 7.640

8.  Tumour suppressors miR-1 and miR-133a target the oncogenic function of purine nucleoside phosphorylase (PNP) in prostate cancer.

Authors:  S Kojima; T Chiyomaru; K Kawakami; H Yoshino; H Enokida; N Nohata; M Fuse; T Ichikawa; Y Naya; M Nakagawa; N Seki
Journal:  Br J Cancer       Date:  2011-11-08       Impact factor: 7.640

Review 9.  OncomiRs: the discovery and progress of microRNAs in cancers.

Authors:  William C S Cho
Journal:  Mol Cancer       Date:  2007-09-25       Impact factor: 27.401

Review 10.  The role of microRNAs in the regulation of apoptosis in lung cancer and its application in cancer treatment.

Authors:  Norahayu Othman; Noor Hasima Nagoor
Journal:  Biomed Res Int       Date:  2014-06-05       Impact factor: 3.411

View more
  21 in total

1.  Evaluation of Silencing Effect of miR-133a-5p Mimic on TIM-3 Expression in AML (HL-60) Cell Line.

Authors:  Zohreh Hojati; Mazdak Ganjalikhani-Hakemi; Mahnaz Ameri; Seyedeh Fatemeh Alimohammadi-Jelodar; Moein Dehbashi; Maryam Mohammad Ganji; Vida Homayouni; Hossein Khanahmad
Journal:  Indian J Clin Biochem       Date:  2019-06-04

2.  Anti-proliferative role and prognostic implication of miR-141 in gastric cancer.

Authors:  Mingwei Huang; Liucheng Wu; Yuzhou Qin; Zhao Li; Shanshan Luo; Haiquan Qin; Yang Yang; Jiansi Chen
Journal:  Am J Transl Res       Date:  2016-08-15       Impact factor: 4.060

3.  MIR133A regulates cell proliferation, migration, and apoptosis by targeting SOX9 in human colorectal cancer cells.

Authors:  Santosh Lamichhane; Ji-Su Mo; Grinsun Sharma; Sun-Myoung Joung; Soo-Cheon Chae
Journal:  Am J Cancer Res       Date:  2022-07-15       Impact factor: 5.942

4.  The long coding RNA AFAP1-AS1 promotes tumor cell growth and invasion in pancreatic cancer through upregulating the IGF1R oncogene via sequestration of miR-133a.

Authors:  Bo Chen; Qinhua Li; Yongping Zhou; Xujing Wang; Qiqi Zhang; Yongkun Wang; Huiren Zhuang; Xiaohua Jiang; Wujun Xiong
Journal:  Cell Cycle       Date:  2018       Impact factor: 4.534

5.  MiR-133a-3p relieves the oxidative stress induced trophoblast cell apoptosis through the BACH1/Nrf2/HO-1 signaling pathway.

Authors:  H Guo; Y Wang; W Jia; L Liu
Journal:  Physiol Res       Date:  2021-01-14       Impact factor: 1.881

6.  Prognostic value of decreased microRNA-133a in solid cancers: a meta-analysis.

Authors:  Jian Xiao; Yong Zou; Xiaoxiao Lu; Bin Xie; Qiao Yu; Baimei He; Bixiu He; Qiong Chen
Journal:  Onco Targets Ther       Date:  2016-09-21       Impact factor: 4.147

7.  MicroRNA-133a functions as a tumor suppressor by targeting IGF-1R in hepatocellular carcinoma.

Authors:  Wei Zhang; Kai Liu; Songyang Liu; Bai Ji; Yingchao Wang; Yahui Liu
Journal:  Tumour Biol       Date:  2015-07-10

Review 8.  LncRNA DDX11-AS1: a novel oncogene in human cancer.

Authors:  Yubin Feng; Maomao Wu; Shuang Hu; Xiaoqing Peng; Feihu Chen
Journal:  Hum Cell       Date:  2020-08-09       Impact factor: 4.174

9.  miR-449a targets Flot2 and inhibits gastric cancer invasion by inhibiting TGF-β-mediated EMT.

Authors:  Qian Li; Jie Peng; Xinhua Li; Aimin Leng; Ting Liu
Journal:  Diagn Pathol       Date:  2015-11-14       Impact factor: 2.644

10.  Comparison of the miRNA profiles in HPV-positive and HPV-negative tonsillar tumors and a model system of human keratinocyte clones.

Authors:  Zuzana Vojtechova; Ivan Sabol; Martina Salakova; Jana Smahelova; Jiri Zavadil; Lubomir Turek; Marek Grega; Jan Klozar; Bohumir Prochazka; Ruth Tachezy
Journal:  BMC Cancer       Date:  2016-07-04       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.